Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma

Prior treatment

• Under treatment of high-dose progestin therapy more than 1 months in recent 6 months
• Already diagnosed with hyperlipidemia and using lipid-lowering drugs

Other illness

• Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
• Confirmed diagnosis of any cancer in reproductive system
• Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
• Hypersensitivity or contradiction for using MA or atorvastatin

Other

• Pregnancy or potential pregnancy
• With other factors of reproductive dysfunction;
• Strong request for uterine removal or other conservative treatment
• Smoker (\>15 cigarettes a day)
• Drinker (\>20 grams a day)

• Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove well-differentiated EEC G1 without myometrial invasion
• No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
• Have a desire for remaining reproductive function or uterus
• Good compliance with adjunctive treatment and follow-up
• Abnormal blood lipid. At least meet one of the following five items:
  • Total cholesterol (TC) ≥ 5.2mmol/L (200mg/dL)
  • Low-density lipoprotein cholesterol (LDL-C) ≥ 3.4mmol/L (130mg/dL)
  • Fasting triglycerides (TG) ≥ 1.7mmol/L (150mg/dL)
  • High-density lipoprotein cholesterol (HDL-C) \< 1.03mmol/L (40mg/dL)
  • Apo-lipoprotein-A (Apo-A) \< 1.0g/L